Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Kellie T, Kostopoulos"'
Autor:
Deric L. Wheeler, Ravi Salgia, Kari B. Wisinski, David Yang, Matthew J. Wleklinski, Kelsey L. Corrigan, Kellie T. Kostopoulos, Neha Luthar, Emily F. Dunn, Mari Iida, Toni M. Brand
PDF - 3969K, Supplemental Figure 1. Therapeutic inhibition of SFKs can block nEGFR translocation in colorectal tumor models.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d3c68d43f02642b37d7b611c071ee1e
https://doi.org/10.1158/1535-7163.22500735
https://doi.org/10.1158/1535-7163.22500735
Autor:
Deric L. Wheeler, Ravi Salgia, Kari B. Wisinski, David Yang, Matthew J. Wleklinski, Kelsey L. Corrigan, Kellie T. Kostopoulos, Neha Luthar, Emily F. Dunn, Mari Iida, Toni M. Brand
PDF - 69K, Legend for Supplementary Figure 1.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::356c87b12aea6ab844b4eb1744aed259
https://doi.org/10.1158/1535-7163.22500732
https://doi.org/10.1158/1535-7163.22500732
Autor:
Deric L. Wheeler, David T. Yang, Kellie T. Kostopoulos, Mari Iida, Emily F. Dunn, Neha Luthar, Toni M. Brand, Matthew J. Wleklinski, Kelsey L. Corrigan, Kari B. Wisinski, Ravi Salgia
Publikováno v:
Molecular Cancer Therapeutics. 13:1356-1368
Triple-negative breast cancer (TNBC) is a subclass of breast cancers (i.e., estrogen receptor–negative, progesterone receptor–negative, and HER2-negative) that have poor prognosis and very few identified molecular targets. Strikingly, a high perc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d94a5ad99672d4acf1dabba87821ff13
https://doi.org/10.1158/1535-7163.mct-13-1021
https://doi.org/10.1158/1535-7163.mct-13-1021
Autor:
Toni M, Brand, Mari, Iida, Emily F, Dunn, Neha, Luthar, Kellie T, Kostopoulos, Kelsey L, Corrigan, Matthew J, Wleklinski, David, Yang, Kari B, Wisinski, Ravi, Salgia, Deric L, Wheeler
Publikováno v:
Molecular Cancer Therapeutics. 18:868-868
Triple-negative breast cancer (TNBC) is a subclass of breast cancers (i.e. estrogen receptor negative, progesterone receptor negative, and HER2 negative) that have poor prognosis and very few identified molecular targets. Strikingly, a high percentag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91cd7eea588a1709839f74248373ce72
https://doi.org/10.1158/1535-7163.mct-18-1183
https://doi.org/10.1158/1535-7163.mct-18-1183
Autor:
Chunrong Li, Toni M. Brand, Mari Iida, Chimera R. Peet, Rebecca A. Myers, Deric L. Wheeler, Kellie T. Kostopoulos, Emily F. Dunn
Publikováno v:
Cancer Biology & Therapy. 12:436-446
The epidermal growth factor receptor (EGFR) is a ubiquitously expressed receptor tyrosine kinase (RTK) and is recognized as a key mediator of tumorigenesis in many human tumors. Currently there are five EGFR inhibitors used in oncology, two monoclona
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79fbfd31335adabbe2b7cef8d6b30d9b
https://doi.org/10.4161/cbt.12.5.16394
https://doi.org/10.4161/cbt.12.5.16394
Autor:
Matthew J. Wleklinski, Toni M. Brand, Mari Iida, Deric L. Wheeler, Kellie T. Kostopoulos, Neha Luthar
Publikováno v:
Cancer Research. 73:LB-219
Triple negative breast cancer (TNBC) is a subclass of breast cancer (i.e. estrogen receptor negative, progesterone receptor negative, and HER-2 negative) that has poor prognosis and very few identified molecular targets. Strikingly the majority of TN
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::731cd1e6472455fb15b18ccf8c90d0a9
https://doi.org/10.1158/1538-7445.am2013-lb-219
https://doi.org/10.1158/1538-7445.am2013-lb-219